Samjin Pharmaceutical Secures Exclusive Domestic Supply of Ontact Health's Cardiac Ultrasound AI Solution

Samjin Pharmaceutical is expanding its portfolio beyond pharmaceuticals to include AI-based medical devices.

From left, Sangjin Kim, President of Samjin Pharmaceutical, and Hyukjae Jang, CEO of Ontact Health, are taking a commemorative photo at the business agreement ceremony for the exclusive domestic supply of the cardiac ultrasound AI solution 'SONIX HEALTH'.
Photo by Samjin Pharmaceutical

원본보기 아이콘

On May 6, Samjin Pharmaceutical announced that it has signed a business agreement with AI-based medical and healthcare company Ontact Health for the exclusive domestic supply of the cardiac ultrasound AI solution ‘SONIX HEALTH’. Based on this agreement, the two companies plan to expand the introduction of SONIX HEALTH to medical institutions across Korea and carry out joint marketing activities.

SONIX HEALTH is an AI-based automated cardiac ultrasound analysis solution that has obtained U.S. FDA 510(k) clearance and Medical Device Class II certification from the Ministry of Food and Drug Safety (MFDS) in Korea. Previously, cardiac ultrasound interpretation relied heavily on the examiner’s proficiency and subjective judgment, typically taking an average of 60 to 90 minutes. However, according to the company, SONIX HEALTH uses one-click AI automated analysis to reduce examination time by more than 70%.

The technical performance of the solution has also been validated through clinical studies. Image classification accuracy rates are 96% for B-mode, 99% for Doppler, and 100% for M-mode, while the correlation coefficient for automated left ventricular deformation (LV GLS) analysis is 0.97. The solution supports the entire end-to-end examination process, from quantitative measurement and qualitative assessment to interpretation summary, prescription, and transfer recommendations. As of the end of last year, it was in use at approximately 3,000 medical institutions both in Korea and overseas.

Through this agreement, Samjin Pharmaceutical is expanding its business scope into the digital healthcare sector. By adding the exclusive supply of SONIX HEALTH to its existing electrocardiogram Holter monitoring device ‘S-Patch Ex’, the company plans to build a comprehensive lineup of cardiovascular diagnostic solutions.

Hyukjae Jang, CEO of Ontact Health, stated, “Through this agreement with Samjin Pharmaceutical, we are accelerating the expansion of SONIX HEALTH in the Korean market. The collaboration between the two companies will further enhance the quality of cardiac ultrasound diagnosis at primary healthcare sites.” Sangjin Kim, President of Samjin Pharmaceutical, commented, “By combining Ontact Health’s AI technology with Samjin Pharmaceutical’s medical institution network, we aim to increase the early diagnosis rate of cardiac diseases in Korea and contribute to building a patient-centered healthcare environment.”

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.